Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 5718: TGN-1062, a dual CDK7 and FLT3 Inhibitor, shows potent anti-AML activity and synergizes with Venetoclax

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTrason ThodeLNLe Xuan Truong NguyenCity Of Hope National Medical CenterBDBrian DurbinTranslational Genomics Research Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Thode et al. (2024) studied this question.

synapsesocial.com/papers/68e72ce5b6db6435876a6d43https://doi.org/10.1158/1538-7445.am2024-5718
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 3896: MERTK inhibitor MRX-2843 sensitizes AML to venetoclax and azacitidine in preclinical models.2026
  2. 2Abstract 7218: Venetoclax triggers apoptosis and augments the effectiveness of doxorubicin against acute myeloid leukemia cells2024
  3. 3Abstract 7089: Proteomic evaluation of combination data in acute myeloid leukemia to inform mechanism of action and new targets2024
  4. 4Abstract 4466: Clinical-grade CK2 inhibitor CX-4945 synergistically enhances venetoclax-mediated antileukemic activity in preclinical acute myeloid leukemia models.2026
  5. 5Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia2018 · 148 citations